Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Utility of Histologic and Histochemical Screening for 16S Ribosomal RNA Gene Sequencing of Formalin-Fixed, Paraffin-Embedded Tissue for Bacterial Endocarditis.

Solomon IH, Lin C, Horback KL, Kanjilal S, Rojas-Rudilla V, Brigl M, Laga AC, Lindeman NI, Padera RF.

Am J Clin Pathol. 2019 Jun 7. pii: aqz055. doi: 10.1093/ajcp/aqz055. [Epub ahead of print]

PMID:
31172185
2.

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M.

Lancet Oncol. 2019 Jul;20(7):1011-1022. doi: 10.1016/S1470-2045(19)30277-3. Epub 2019 May 28.

PMID:
31151904
3.

Targeted Cancer Next-Generation Sequencing as a Primary Screening Tool for Microsatellite Instability and Lynch Syndrome in Upper Gastrointestinal Tract Cancers.

Christakis AG, Papke DJ, Nowak JA, Yurgelun MB, Agoston AT, Lindeman NI, MacConaill LE, Sholl LM, Dong F.

Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1246-1251. doi: 10.1158/1055-9965.EPI-18-1250. Epub 2019 Apr 26.

PMID:
31028081
4.

Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the BRAF, EGFR, and KRAS Genes: A Study of the College of American Pathologists Molecular Oncology Committee.

Moncur JT, Bartley AN, Bridge JA, Kamel-Reid S, Lazar AJ, Lindeman NI, Long TA, Merker JD, Rai AJ, Rimm DL, Rothberg PG, Vasalos P, Kim AS.

Arch Pathol Lab Med. 2019 Apr 10. doi: 10.5858/arpa.2018-0396-CP. [Epub ahead of print]

PMID:
30969158
5.

Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer.

Veneris JT, Lee EK, Goebel EA, Nucci MR, Lindeman N, Horowitz NS, Lee L, Raut CP, Crotzer D, Matulonis U, Konstantinopoulos PA, Campos S.

Gynecol Oncol. 2019 Jun;153(3):471-478. doi: 10.1016/j.ygyno.2019.03.247. Epub 2019 Mar 29.

PMID:
30935717
6.

POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure.

Lee EK, Lindeman NI, Matulonis UA, Konstantinopoulos PA.

Gynecol Oncol Rep. 2019 Jan 29;28:15-17. doi: 10.1016/j.gore.2019.01.012. eCollection 2019 May.

7.

Utility of a Simple and Robust Flow Cytometry Assay for Rapid Clonality Testing in Mature Peripheral T-Cell Lymphomas.

Novikov ND, Griffin GK, Dudley G, Drew M, Rojas-Rudilla V, Lindeman NI, Dorfman DM.

Am J Clin Pathol. 2019 Apr 2;151(5):494-503. doi: 10.1093/ajcp/aqy173.

PMID:
30715093
8.

Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer.

Chen IX, Chauhan VP, Posada J, Ng MR, Wu MW, Adstamongkonkul P, Huang P, Lindeman N, Langer R, Jain RK.

Proc Natl Acad Sci U S A. 2019 Jan 30. pii: 201815515. doi: 10.1073/pnas.1815515116. [Epub ahead of print]

PMID:
30700545
9.

Clinicopathologic and genetic characteristics of interval colorectal carcinomas favor origin from missed or incompletely excised precursors.

Soong TR, Nayor J, Stachler MD, Perencevich M, Jajoo K, Saltzman JR, Lindeman NI, Srivastava A.

Mod Pathol. 2019 May;32(5):666-674. doi: 10.1038/s41379-018-0176-6. Epub 2018 Nov 19.

PMID:
30455417
10.

Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays.

Merker JD, Devereaux K, Iafrate AJ, Kamel-Reid S, Kim AS, Moncur JT, Montgomery SB, Nagarajan R, Portier BP, Routbort MJ, Smail C, Surrey LF, Vasalos P, Lazar AJ, Lindeman NI.

Arch Pathol Lab Med. 2019 Apr;143(4):463-471. doi: 10.5858/arpa.2018-0336-CP. Epub 2018 Oct 30.

PMID:
30376374
11.

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.

Mansouri A, Hachem LD, Mansouri S, Nassiri F, Laperriere NJ, Xia D, Lindeman NI, Wen PY, Chakravarti A, Mehta MP, Hegi ME, Stupp R, Aldape KD, Zadeh G.

Neuro Oncol. 2019 Feb 14;21(2):167-178. doi: 10.1093/neuonc/noy132.

PMID:
30189035
12.

Targeted Genomic Profiling of Female Adnexal Tumors of Probable Wolffian Origin (FATWO).

Mirkovic J, Dong F, Sholl LM, Garcia E, Lindeman N, MacConaill L, Crum CP, Nucci MR, McCluggage WG, Howitt BE.

Int J Gynecol Pathol. 2018 Aug 21. doi: 10.1097/PGP.0000000000000545. [Epub ahead of print]

PMID:
30134342
13.

Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma.

Papke DJ Jr, Nowak JA, Yurgelun MB, Frieden A, Srivastava A, Lindeman NI, Sholl LM, MacConaill LE, Dong F.

Mod Pathol. 2018 Dec;31(12):1882-1890. doi: 10.1038/s41379-018-0091-x. Epub 2018 Jun 28.

PMID:
29955144
14.

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.

Gockley AA, Kolin DL, Awtrey CS, Lindeman NI, Matulonis UA, Konstantinopoulos PA.

Gynecol Oncol. 2018 Aug;150(2):219-226. doi: 10.1016/j.ygyno.2018.05.028. Epub 2018 Jun 22.

PMID:
29937315
15.

Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma.

Gupta N, Goumnerova LC, Manley P, Chi SN, Neuberg D, Puligandla M, Fangusaro J, Goldman S, Tomita T, Alden T, DiPatri A, Rubin JB, Gauvain K, Limbrick D, Leonard J, Geyer JR, Leary S, Browd S, Wang Z, Sood S, Bendel A, Nagib M, Gardner S, Karajannis MA, Harter D, Ayyanar K, Gump W, Bowers DC, Weprin B, MacDonald TJ, Aguilera D, Brahma B, Robison NJ, Kiehna E, Krieger M, Sandler E, Aldana P, Khatib Z, Ragheb J, Bhatia S, Mueller S, Banerjee A, Bredlau AL, Gururangan S, Fuchs H, Cohen KJ, Jallo G, Dorris K, Handler M, Comito M, Dias M, Nazemi K, Baird L, Murray J, Lindeman N, Hornick JL, Malkin H, Sinai C, Greenspan L, Wright KD, Prados M, Bandopadhayay P, Ligon KL, Kieran MW.

Neuro Oncol. 2018 Oct 9;20(11):1547-1555. doi: 10.1093/neuonc/noy070.

16.

SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma.

Kolin DL, Dong F, Baltay M, Lindeman N, MacConaill L, Nucci MR, Crum CP, Howitt BE.

Mod Pathol. 2018 Sep;31(9):1442-1456. doi: 10.1038/s41379-018-0049-z. Epub 2018 Apr 26.

PMID:
29700418
17.

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.

Edelman G, Rodon J, Lager J, Castell C, Jiang J, Van Allen EM, Wagle N, Lindeman NI, Sholl LM, Shapiro GI.

Oncologist. 2018 Apr;23(4):401-e38. doi: 10.1634/theoncologist.2017-0691. Epub 2018 Mar 28.

18.

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC.

J Clin Oncol. 2018 Jun 1;36(16):1631-1641. doi: 10.1200/JCO.2017.76.8671. Epub 2018 Mar 5. Review.

PMID:
29504847
19.

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC.

Arch Pathol Lab Med. 2018 Oct;142(10):1242-1253. doi: 10.5858/arpa.2018-0901-SA. Epub 2018 Mar 5. Review.

PMID:
29504834
20.

Mutational landscape of goblet cell carcinoids and adenocarcinoma ex goblet cell carcinoids of the appendix is distinct from typical carcinoids and colorectal adenocarcinomas.

Johncilla M, Stachler M, Misdraji J, Lisovsky M, Yozu M, Lindeman N, Lauwers GY, Odze RD, Srivastava A.

Mod Pathol. 2018 Jun;31(6):989-996. doi: 10.1038/s41379-018-0003-0. Epub 2018 Feb 8.

21.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

J Mol Diagn. 2018 Mar;20(2):129-159. doi: 10.1016/j.jmoldx.2017.11.004. Epub 2018 Jan 23.

PMID:
29398453
22.

Molecular Testing of Nodules with a Suspicious or Malignant Cytologic Diagnosis in the Setting of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP).

Strickland KC, Eszlinger M, Paschke R, Angell TE, Alexander EK, Marqusee E, Nehs MA, Jo VY, Lowe A, Vivero M, Hollowell M, Qian X, Wieczorek T, French CA, Teot LA, Cibas ES, Lindeman NI, Krane JF, Barletta JA.

Endocr Pathol. 2018 Mar;29(1):68-74. doi: 10.1007/s12022-018-9515-x.

PMID:
29396809
23.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

J Thorac Oncol. 2018 Mar;13(3):323-358. doi: 10.1016/j.jtho.2017.12.001. Epub 2018 Jan 25.

24.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

Arch Pathol Lab Med. 2018 Mar;142(3):321-346. doi: 10.5858/arpa.2017-0388-CP. Epub 2018 Jan 22. Review.

PMID:
29355391
25.

Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma.

Stover EH, Feltmate C, Berkowitz RS, Lindeman NI, Matulonis UA, Konstantinopoulos PA.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00135. Epub 2018 Nov 8. No abstract available.

26.

Authors' Reply.

Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN.

J Mol Diagn. 2018 Jan;20(1):125-126. doi: 10.1016/j.jmoldx.2017.11.002.

27.

Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing.

Kim AS, Bartley AN, Bridge JA, Kamel-Reid S, Lazar AJ, Lindeman NI, Long TA, Merker JD, Rai AJ, Rimm DL, Rothberg PG, Vasalos P, Moncur JT.

JAMA Oncol. 2018 Jun 1;4(6):838-841. doi: 10.1001/jamaoncol.2017.4021.

28.

Somatic mutations in CDH1 and CTNNB1 in primary carcinomas at 13 anatomic sites.

Busch EL, Hornick JL, Umeton R, Albayrak A, Lindeman NI, MacConaill LE, Garcia EP, Ducar M, Rebbeck TR.

Oncotarget. 2017 Sep 21;8(49):85680-85691. doi: 10.18632/oncotarget.21115. eCollection 2017 Oct 17.

29.

Worldwide Frequency of Commonly Detected EGFR Mutations.

Graham RP, Treece AL, Lindeman NI, Vasalos P, Shan M, Jennings LJ, Rimm DL.

Arch Pathol Lab Med. 2018 Feb;142(2):163-167. doi: 10.5858/arpa.2016-0579-CP. Epub 2017 Nov 6.

PMID:
29106293
30.

A Window Into Clinical Next-Generation Sequencing-Based Oncology Testing Practices.

Nagarajan R, Bartley AN, Bridge JA, Jennings LJ, Kamel-Reid S, Kim A, Lazar AJ, Lindeman NI, Moncur J, Rai AJ, Routbort MJ, Vasalos P, Merker JD.

Arch Pathol Lab Med. 2017 Dec;141(12):1679-1685. doi: 10.5858/arpa.2016-0542-CP. Epub 2017 Oct 13.

PMID:
29028368
31.

Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.

Mirkovic J, McFarland M, Garcia E, Sholl LM, Lindeman N, MacConaill L, Dong F, Hirsch M, Nucci MR, Quick CM, Crum CP, McCluggage WG, Howitt BE.

Am J Surg Pathol. 2018 Feb;42(2):227-233. doi: 10.1097/PAS.0000000000000958.

PMID:
28984674
32.

HPV-16 in a distinct subset of oral epithelial dysplasia.

Lerman MA, Almazrooa S, Lindeman N, Hall D, Villa A, Woo SB.

Mod Pathol. 2017 Dec;30(12):1646-1654. doi: 10.1038/modpathol.2017.71. Epub 2017 Aug 11.

33.

The fuzzy world of precision medicine: deliberations of a precision medicine tumor board.

McGraw SA, Garber J, Jänne PA, Lindeman N, Oliver N, Sholl LM, Van Allen EM, Wagle N, Garraway LA, Joffe S, Gray SW.

Per Med. 2017 Jan;14(1):37-50. doi: 10.2217/pme-2016-0074. Epub 2016 Dec 15.

34.

The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice.

Kuo FC, Mar BG, Lindsley RC, Lindeman NI.

Blood. 2017 Jul 27;130(4):433-439. doi: 10.1182/blood-2017-03-734533. Epub 2017 Jun 9. Review.

35.

Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.

Garcia EP, Minkovsky A, Jia Y, Ducar MD, Shivdasani P, Gong X, Ligon AH, Sholl LM, Kuo FC, MacConaill LE, Lindeman NI, Dong F.

Arch Pathol Lab Med. 2017 Jun;141(6):751-758. doi: 10.5858/arpa.2016-0527-OA. Epub 2017 Mar 3.

PMID:
28557599
36.

Reporting Results of Molecular Tests: A Retrospective Examination of BRAF Mutation Reporting.

Treece AL, Gulley ML, Vasalos P, Paquette C, Lindeman NI, Jennings LJ, Bartley AN.

Arch Pathol Lab Med. 2017 May;141(5):658-665. doi: 10.5858/arpa.2016-0280-CP. Epub 2017 Mar 13.

PMID:
28447902
37.

Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.

Tanguturi SK, Trippa L, Ramkissoon SH, Pelton K, Knoff D, Sandak D, Lindeman NI, Ligon AH, Beroukhim R, Parmigiani G, Wen PY, Ligon KL, Alexander BM.

Neuro Oncol. 2017 Jul 1;19(7):908-917. doi: 10.1093/neuonc/now312.

38.

Clinical and Technical Aspects of Genomic Diagnostics for Precision Oncology.

Sheikine Y, Kuo FC, Lindeman NI.

J Clin Oncol. 2017 Mar 20;35(9):929-933. doi: 10.1200/JCO.2016.70.7539. Epub 2017 Feb 13. Review.

PMID:
28297627
39.

Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study.

Ghazani AA, Oliver NM, St Pierre JP, Garofalo A, Rainville IR, Hiller E, Treacy DJ, Rojas-Rudilla V, Wood S, Bair E, Parello M, Huang F, Giannakis M, Wilson FH, Stover EH, Corsello SM, Nguyen T, Rana HQ, Church AJ, Lowenstein C, Cibulskis C, Amin-Mansour A, Heng J, Brais L, Santos A, Bauer P, Waldron A, Lo P, Gorman M, Lydon CA, Welch M, McNamara P, Gabriel S, Sholl LM, Lindeman NI, Garber JE, Joffe S, Van Allen EM, Gray SW, Ja Nne PA, Garraway LA, Wagle N.

Genet Med. 2017 Jul;19(7):787-795. doi: 10.1038/gim.2016.191. Epub 2017 Jan 26.

PMID:
28125075
40.

Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of "Carcinomas" Harboring RAS Mutations.

Paulson VA, Shivdasani P, Angell TE, Cibas ES, Krane JF, Lindeman NI, Alexander EK, Barletta JA.

Thyroid. 2017 Apr;27(4):506-511. doi: 10.1089/thy.2016.0583. Epub 2017 Feb 24.

PMID:
28114855
41.

Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors.

Ramkissoon SH, Bandopadhayay P, Hwang J, Ramkissoon LA, Greenwald NF, Schumacher SE, O'Rourke R, Pinches N, Ho P, Malkin H, Sinai C, Filbin M, Plant A, Bi WL, Chang MS, Yang E, Wright KD, Manley PE, Ducar M, Alexandrescu S, Lidov H, Delalle I, Goumnerova LC, Church AJ, Janeway KA, Harris MH, MacConaill LE, Folkerth RD, Lindeman NI, Stiles CD, Kieran MW, Ligon AH, Santagata S, Dubuc AM, Chi SN, Beroukhim R, Ligon KL.

Neuro Oncol. 2017 Jul 1;19(7):986-996. doi: 10.1093/neuonc/now294.

42.

Molecular testing of different cytologic preparations in patients with advanced lung adenocarcinoma: which yields the best results?

Vivero M, Wang CI, Jo VY, Hollowell M, Cibas ES, Lindeman NI, Lowe AC.

J Am Soc Cytopathol. 2017 Jan - Feb;6(1):16-23. doi: 10.1016/j.jasc.2016.06.002. Epub 2016 Jun 17.

PMID:
31042629
43.

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.

Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN.

J Mol Diagn. 2017 Jan;19(1):4-23. doi: 10.1016/j.jmoldx.2016.10.002. Review.

44.

Institutional implementation of clinical tumor profiling on an unselected cancer population.

Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, Nishino M, Janeway KA, Church A, Harris M, Ritterhouse LL, Campbell JD, Rojas-Rudilla V, Ligon AH, Ramkissoon S, Cleary JM, Matulonis U, Oxnard GR, Chao R, Tassell V, Christensen J, Hahn WC, Kantoff PW, Kwiatkowski DJ, Johnson BE, Meyerson M, Garraway LA, Shapiro GI, Rollins BJ, Lindeman NI, MacConaill LE.

JCI Insight. 2016 Nov 17;1(19):e87062. doi: 10.1172/jci.insight.87062.

45.

Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing.

Nowak JA, Yurgelun MB, Bruce JL, Rojas-Rudilla V, Hall DL, Shivdasani P, Garcia EP, Agoston AT, Srivastava A, Ogino S, Kuo FC, Lindeman NI, Dong F.

J Mol Diagn. 2017 Jan;19(1):84-91. doi: 10.1016/j.jmoldx.2016.07.010. Epub 2016 Nov 15.

46.

Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA.

Watkins JC, Howitt BE, Horowitz NS, Ritterhouse LL, Dong F, MacConaill LE, Garcia E, Lindeman NI, Lee LJ, Berkowitz RS, Nucci MR, Crum CP.

Mod Pathol. 2017 Mar;30(3):448-458. doi: 10.1038/modpathol.2016.187. Epub 2016 Nov 11.

47.

The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR.

Xia D, Reardon DA, Bruce JL, Lindeman NI.

J Mol Diagn. 2016 Nov;18(6):864-871. doi: 10.1016/j.jmoldx.2016.06.009. Epub 2016 Sep 15. Erratum in: J Mol Diagn. 2017 Mar;19(2):338.

PMID:
27639200
48.

Clinical, Sonographic, and Pathological Characteristics of RAS-Positive Versus BRAF-Positive Thyroid Carcinoma.

Kakarmath S, Heller HT, Alexander CA, Cibas ES, Krane JF, Barletta JA, Lindeman NI, Frates MC, Benson CB, Gawande AA, Cho NL, Nehs M, Moore FD, Marqusee E, Kim MI, Larsen PR, Kwong N, Angell TE, Alexander EK.

J Clin Endocrinol Metab. 2016 Dec;101(12):4938-4944. Epub 2016 Sep 30.

49.

Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology.

Layfield LJ, Roy-Chowdhuri S, Baloch Z, Ehya H, Geisinger K, Hsiao SJ, Lin O, Lindeman NI, Roh M, Schmitt F, Sidiropoulos N, VanderLaan PA.

Diagn Cytopathol. 2016 Dec;44(12):1000-1009. doi: 10.1002/dc.23549. Epub 2016 Aug 26.

50.

The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.

Garofalo A, Sholl L, Reardon B, Taylor-Weiner A, Amin-Mansour A, Miao D, Liu D, Oliver N, MacConaill L, Ducar M, Rojas-Rudilla V, Giannakis M, Ghazani A, Gray S, Janne P, Garber J, Joffe S, Lindeman N, Wagle N, Garraway LA, Van Allen EM.

Genome Med. 2016 Jul 26;8(1):79. doi: 10.1186/s13073-016-0333-9.

Supplemental Content

Loading ...
Support Center